Phase
Condition
Cancer/tumors
Neoplasms
Uterine Disorders
Treatment
Electronic Health Record Review
Nutritional Assessment
Educational Intervention
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patients undergoing immunotherapy for their first time
Age ≥ 18 years
Body mass index (BMI) > 19
Histological confirmation of advanced stage malignancies (stage 3 or 4) appropriatefor the following types of immunotherapy: PD-1 antibody (nivolumab, pembrolizumab),PD-L1 antibody (atezolizumab, avelumab, durvalumab), CTLA-4 antibody (ipilimumab) orany combination thereof
Exclusion
Exclusion Criteria:
Age < 18 years
Pregnant women
Nursing mothers
Persons of childbearing potential who are unwilling to employ adequate contraception
Patients will be excluded if they are on insulin due to diabetes (diabetic patientswill be asked to monitor their glucose levels with a continuous glucose monitoring [CGM] device), if they have allergies to any of the components in the FMD, if thereis unacceptable deterioration of their nutritional status and cancer progression
Study Design
Study Description
Connect with a study center
Mayo Clinic in Florida
Jacksonville, Florida 32224-9980
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.